Akums Drugs and Pharma's Patent for Sickle Cell Disease Management
Akums Drugs Patent Announcement
Akums Drugs and Pharmaceuticals announced a significant breakthrough with the securing of a patent for its Room Temperature Stable Oral Suspension of Hydroxyurea, specifically designed to manage Sickle Cell Disease (SCD). This patented formulation is a notable advancement in addressing the storage challenges faced by traditional Hydroxyurea solutions, which mandate refrigeration between 2–8°C.
Impact on Patient Care
Sickle Cell Disease is a genetic disorder that leads to severe health complications. Affected individuals often experience symptoms such as anemia and frequent pain episodes, which can greatly diminish quality of life. The new formulation from Akums promises to alleviate these challenges by remaining stable at room temperature, thus enhancing accessibility particularly in regions with scarce cold storage capabilities.
- Key Benefits:
- Improved dose flexibility based on patient weight, especially beneficial for pediatric and adolescent patients.
- Reduced cost compared to imported Hydroxyurea solutions, aligning with Akums' commitment to affordability.
As stated by Sanjeev Jain, Managing Director of Akums, “We are proud to have secured this patent for a formulation that improves the lives of countless SCD patients.” With this advancement, Akums continues to be a leader in healthcare innovation.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.